Multinational phase 2 trial of erdafinitinb for advanced solid tumors with FGFR alterations

FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. The multinational phase 2 RAGNAR trial (156 centers in 15 countries) evaluated erdafitinib for advanced solid tumors of any histology (except urothelial carcinoma) with FGFR1-4 alterations. In the primary cohort of RAGNAR, objective response was seen in 30% of patients (95% CI 24-36) across 16 distinct tumor types. Toxicity was acceptable. The authors conclude that these results support the continued development of FGFR inhibitors for patients with advanced solid tumors.